Are glucagon-like-peptide-1 (GLP-1) receptor agonists useful in treating Parkinson’s disease (PD). Does the clinical trial with lixisenatide add anything?
Parkinson’s disease (PD) is a common neurodegenerative disease. Glucagon-Like-Peptide-1 (GLP-1) receptor agonists decrease the incidence of developing PD, and are being considered for the treatment of PD.A phase 2 clinical...
Read More